Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

PharmacoEconomics - United Kingdom
doi 10.1007/s40273-018-0641-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Economic Impact of the Use of Rifaximin 550 Mg Twice Daily for the Treatment of Overt Hepatic Encephalopathy in Italy

Hepatic Medicine: Evidence and Research
Hepatology
2017English

PWE-153 Cost Effectiveness of Rifaximin-A in the Reduction of Recurrence of Overt Hepatic Encephalopathy

Gut
Gastroenterology
2014English

Rifaximin for the Prevention and Treatment of Hepatic Encephalopathy: A Systematic Review With Meta-Analyses of Randomised Controlled Trials

Journal of Clinical and Experimental Hepatology
Hepatology
2017English

Safety, Efficacy, and Patient Acceptability of Rifaximin for Hepatic Encephalopathy

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2014English

The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis

American Journal of Medicine
Medicine
2016English

L-Ornithine L-Aspartate in Bouts of Overt Hepatic Encephalopathy

Hepatology
MedicineHepatology
2017English

The Economic Burden of Bronchiectasis – Known and Unknown: A Systematic Review

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2019English

The Economic Burden of Physical Inactivity: A Systematic Review and Critical Appraisal

British Journal of Sports Medicine
Sports MedicinePhysical TherapySports ScienceSports TherapyOrthopedicsMedicineRehabilitation
2017English

Grading the Range of Hepatic Encephalopathy From Overt to Covert: Animals to the Rescue!

Hepatology
MedicineHepatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy